To prepare immunomicelles, new targeted carriers for poorly soluble pharmaceuticals, a procedure has been developed to chemically attach mAbs to reactive groups incorporated into the corona of polymeric micelles made of polyethylene glycol-phosphatidylethanolamine conjugates. Micelle-attached antibodies retained their ability to specifically interact with their antigens. Immunomicelles with attached antitumor mAb 2C5 effectively recognized and bound various cancer cells in vitro and showed an increased accumulation in experimental tumors in mice when compared with nontargeted micelles. Intravenous administration of tumor-specific 2C5 immunomicelles loaded with a sparingly soluble anticancer agent, taxol, into experimental mice bearing Lewis lung carcinoma resulted in an increased accumulation of taxol in the tumor compared with free taxol or taxol in nontargeted micelles and in enhanced tumor growth inhibition. This family of pharmaceutical carriers can be used for the solubilization and enhanced delivery of poorly soluble drugs to various pathological sites in the body.
drug delivery ͉ polymeric micelles ͉ monoclonal antibodies ͉ taxol ͉ tumor targeting T he requirements of pharmaceutical drug carriers for i.v. administration include small size, biodegradability, good loading capacity, high content of the drug in a final preparation, prolonged circulation, and ability to accumulate in required areas. These requirements are reasonably well met by some drug carriers (microcapsules, liposomes) used predominantly for water-soluble drugs (1) (2) (3) (4) . Although liposomes can entrap poorly soluble drugs in the hydrophobic bilayer, their loading capacity is limited because of possible membrane destabilization. Thus, the development of drug carriers displaying all of the named properties specifically for the delivery of poorly soluble pharmaceuticals continues to represent a challenge.
Low solubility in water tends to be an intrinsic property of many drugs, including anticancer agents, which often represent polycyclic compounds (5) . The membrane permeability and efficacy of such drugs increases with increasing hydrophobicity (6, 7) . On the other hand, parenteral administration of those intrinsically hydrophobic agents is associated with some problems. Thus, i.v. administration of aggregates formed by undissolved drug in aqueous media can cause embolization of blood capillaries (Յ5 m) before drug penetrates a tumor (8) . Additionally, low solubility of hydrophobic drugs in combination with excretion and metabolic degradation hinders the maintenance of therapeutically significant systemic concentrations.
Micelles are spherical colloidal nanoparticles into which many amphiphilic molecules self-assemble. In water, hydrophobic fragments of amphiphilic molecules form the core of a micelle, which may then be used as a cargo space for poorly soluble pharmaceuticals (9, 10) . Hydrophilic parts of the molecules form the micelle corona. Micelle encapsulation increases bioavailability of poorly soluble drugs, protects them from destruction in biological surroundings, and beneficially modifies their pharmacokinetics and biodistribution (11) . Because of their small size (usually 5-50 nm), micelles demonstrate spontaneous accumulation in pathological areas with leaky vasculature, such as infarct zones (12) and tumors (13, 14) . This phenomenon is known as the enhanced permeability and retention effect (15, 16) .
Polymeric micelles are formed by amphiphilic copolymers and demonstrate a number of attractive properties (17) (18) (19) . Because microparticulate drug carriers are removed from the blood via opsonization-mediated phagocytosis by cells and organs of the reticuloendothelial system (20) , the micelle corona formed by hydrophilic polymer blocks provides longevity to micelles in vivo by preventing their opsonization and capture (21) . Amphiphilic polymers have a low critical micelle concentration, which makes polymeric micelles stable and prevents their rapid dissociation in vivo. The use of lipid moieties as hydrophobic blocks provides an additional stability, because the existence of two hydrocarbon chains contributes considerably to the increased hydrophobic interactions in the micelle's core. Micelles prepared from conjugates of polyethylene glycol (PEG) and diacyllipids, such as phosphatidylethanolamine (PE) are of particular interest (22) .
We have reported some data on polymeric micelles formed by PEG-PE conjugates (23) . Such micelles are stable and longcirculating and can be loaded with a variety of poorly soluble drugs including anticancer drugs, such as taxol and tamoxifen (24, 25) . Because of their small size, these preparations are capable of delivering their load even into poorly permeable tumors in mice with a higher efficiency than other longcirculating micropraticulate carriers (26, 27) .
As with other carriers, the drug delivery potential of polymeric micelles may be enhanced by attaching targeting ligands, including antibodies, to the micelle surface (19) . Such a development would represent the next generation of drug carriers for sparingly soluble pharmaceuticals. Certain attempts to prepare micelles with attached ligands (including antibodies) are known (28) (29) (30) . However, no systematic study on antibody-targeted polymeric micelles (immunomicelles) has been undertaken thus far. This may be explained by the absence of suitable and broadly applicable protocols allowing for the covalent attachment of various antibodies to polymeric micelles.
By adapting the coupling technique we recently developed (31, 32), we have prepared PEG-PE-based immunomicelles modified with mAb 2C5 with nucleosome-restricted specificity reactive toward a variety of different cancer cells (33) and antimyosin mAb 2G4 specific for infarcted areas of the myocardium (34) . Here, we present our results on the preparation and some properties of these carriers for sparingly soluble pharmaceuticals including the ability of 2C5 immunomicelles loaded with a poorly soluble anticancer drug, taxol, to deliver increased quantities of the drug into experimental tumors and provide improved tumor growth inhibition.
Materials and Methods
Materials. PE, PEG-2000-PE, and PE-(lissamine-rhodamine B) were from Avanti Polar Lipids. p-Nitrophenylcarbonyl (pNP)-PEG-PE was synthesized as described (31) . Diethylenetriamine-pentaacetic acid-PE conjugate for radiolabeling micelles with 111 In was synthesized as in ref. 35 . RPMI medium 1640, Eagle's MEM, DMEM, serum-free medium, and heat-inactivated FBS were from Cellgro (Herndon, VA).
111
In with specific radioactivity of 395 Ci͞mg was from Perkin-Elmer. Cancer-specific antinucleosome 2C5 is routinely produced in our laboratory. Taxol was purchased from Sigma and dissolved in Cremophor EL (BASF Bioresearch, Mount Olive, NJ) mixed with ethanol (1:1 by volume) and then further in saline as described (36) . Antimyosin 2G4 was provided by B.-A. Khaw (Northeastern University).
Cell Cultures. Murine Lewis lung carcinoma (LLC) and EL4 T cell lymphoma and human BT20 breast adenocarcinoma cell lines were purchased from the American Type Culture Collection. LLC and BT20 cells were maintained in DMEM with 10% FBS, penicillin͞streptomycin, pyruvate, L-glutamine, and nonessential amino acids. EL4 cells were grown in RPMI medium 1640 with the same additives as above. Cells were grown at 37°C in 5% CO 2 .
Labeling of Antibodies with Carboxyfluorescein (CF).
A 50-l aliquot of 2 mM 5-CF succinimidyl ester (Molecular Probes) in DMSO was added to 2 ml of a 12 M solution of 2C5 in 50 mM Tris-buffered saline (TBS), pH 9.0. The mixture was incubated overnight at 4°C. Free CF was removed by dialysis against TBS.
Preparation of Immunomicelles.
A lipid film was prepared by removing chloroform from the mixed solution of PEG 2000 -PE and 2-8 mol percent of pNP-PEG-PE under vacuum. To load micelles, taxol dissolved in methanol was added to a chloroform solution of PEG-PE and pNP-PEG-PE (1.5 mg taxol per 80 mg PEG-PE). When required, trace amounts of diethylenetriaminepentaacetic acid-PE and͞or 0.5 mol percent of PE-(lissaminerhodamine B) were added to these preparations. To form micelles, the film was rehydrated at 50°C in a 5 mM Na citrate-buffered saline, pH 5.0, and vortexed for 5 min.
When required, 0.5 ml of a 12 M solution of 2C5 or 2G4 in borate, pH 9.0 was added to 0.5 ml of pNP-PEG-PE-containing micelles with a PEG-PE concentration of 1.5 mM. The mixture was incubated for 3 h at room temperature and dialyzed against 10 mM Hepes-buffered saline, pH 7.4 (HBS), using cellulose ester membranes with a cut-off size of 300,000 Da (Spectrum Medical Industries). To assess the quantity of the micelle-bound protein, carboxyfluorescein-labeled antibody was used. Protein concentration was measured by associated fluorescence at an excitation wavelength of 490 nm and an emission of 520 nm on a F-2000 spectrofluorimeter (Hitachi, Tokyo). The micelle size was measured by dynamic light scattering with a N4 Plus Submicron Particle System (Coulter) at a PEG-PE concentration of 2-10 mM.
Freeze-Fracture Electron Microscopy. The sample was quenched by using the sandwich technique and liquid nitrogen-cooled propane. A cooling rate of 10,000 K͞s avoids ice crystal formation and cryofixation-caused artifacts. The fracturing process was carried out in JEOL JED-9000 freeze-etching equipment, and the exposed fracture planes were shadowed with Pt for 30 s at an angle of 25-35°followed with carbon for 35 s (2 kV, 60-70 mA, 1 ϫ 10 Ϫ5 Torr). The replicas were cleaned with fuming HNO 3 for 24-36 h followed by repeated agitation with chloroform͞ methanol (1:1 vol͞vol) at least five times and examined with a JEOL 100 CX electron microscope.
Radiolabeling of Micelles. Diethylenetriaminepentaacetic acid-PE-containing micelles in HBS were mixed with 50-100 Ci of 111 In in 0.1 M Na-citrate, pH 3.7. The mixture was incubated for 1 h at room temperature and dialyzed against at least 3,000-fold excess of HBS overnight at 4°C to remove unbound 111 In.
Binding of Immunomicelles to Substrate Monolayers. ELISA plates were coated with 50 l of 10 g͞ml nucleosomes (Worthington) for testing 2C5 immunomicelles or with 50 l of 10 g͞ml cardiac myosin for testing 2G4 immunomicelles and incubated overnight at 4°C. The rinsed plates were coated with 1% FBS in HBS. To substrate-coated plates, 50 l of 2C5 or 2G4 immunomicelles at 20 g͞ml PEG-PE was added and incubated for 4 h at room temperature. The plates were washed with HBS and coated with horseradish peroxidase-antimouse IgG conjugate (ICN) following the manufacturer's recommendations. The conjugate was removed after 3 h at room temperature, and the plates were washed with HBS. Bound peroxidase was quantified by degradation of diaminobenzidine (Neogen, Lexington, KY) supplied as a ready-for-use solution. Color intensity was analyzed by a Multiscan 340 ELISA reader (Labsystems, Helsinki).
Interaction of 2C5 Immunomicelles with Cancer Cells in Vitro.
After initial passage in tissue culture flasks, LLC and BT20 cells were grown on cover slips placed in 6-well tissue culture plates. After the cells reached a confluence of 60-70%, the plates were washed with Hank's buffer and treated with 1% BSA in Eagle's MEM (2 ml per well) and incubated for 1 h at 37°C, 5% CO 2 . To these cells, PE-(lissamine-rhodamine B)-labeled 2C5 immunomicelles were added to a final concentration of PEG-PE of 0.15 mg͞ml and incubated for 1 h at 37°C, 5% CO 2 . After incubation, the cells were washed with Hanks' buffer, and the cover slips were mounted cell-side down on glass slides by using fluorescence-free glycerol-based mounting medium (Fluoromount-G; Southern Biotechnology Associates).
EL4 cells were grown in suspension to the density of Ϸ2 ϫ 10 4 cells per ml, centrifuged at 700 ϫ g for 10 min, and transferred to Hanks' buffer. The cells were washed and resuspended in Hanks' buffer at Ϸ1 ϫ 10 5 cells per ml density. PE-(lissaminerhodamine B)-labeled immunomicelles were added to the EL4 cell suspension to a final PEG-PE concentration of 0.15 mg͞ml. The cells were incubated with immunomicelles for 1 h at 37°C, 5% CO 2 , washed with Hanks' buffer, concentrated to a cell density of 1 ϫ 10 6 cells per ml, transferred to glass slides, and mounted as described. Mounted cells were studied with a Nikon Eclipse E400 microscope under bright light or under epifluorescence with a rhodamine filter. In-labeled micellar formulations via the tail vein. At 30 min and 2 h postinjection, mice were killed, and tumors and muscle samples were collected and analyzed for the presence of 111 In radioactivity. There were five animals per group for each time point.
To estimate the accumulation of free and micellar taxol in tumors, LLC-bearing mice were injected with the same quantity of taxol in Cremophor EL͞ethanol͞saline mixture (see above) or in plain PEG-PE micelles or 2C5 immunomicelles (Ϸ100 g of taxol per animal). At 30 min and 2 h postinjection, mice were killed, and tumors were removed, washed with saline, and homogenized in the presence of 2.5 times the tumor weight of saline by using a PowerGen 125 tissue homogenizer (Fisher). Taxol was extracted and quantified by HPLC as in ref. 37 . tretButyl methyl ether used to extract taxol from homogenates contained 30 g͞ml of N-octylbenzamidine used as an internal HPLC standard and synthesized as in ref. 38 . The HPLC was run on a reverse-phase LiChrospher RP18-5 column (Merck) at flow rate of 0.9 ml͞min with the detection of taxol and the internal standard by optical density at 227 nm.
Inhibition of Tumor Growth with Different Taxol Preparations.
Mice with LLC tumors were injected with different taxol formulations on day 10 postinoculation (Ϸ100 g of taxol per animal per injection). On day 5 after the first administration, the injections were repeated. Twenty days after the first injection, the mice were killed, and tumors were extracted, rinsed twice with saline, wiped, and weighed. There were five mice in each experimental group.
All experimental results are shown as mean values Ϯ standard deviations.
Results and Discussion
Preparation of Activated Micelles and Antibody Attachment. Immunomicelles were prepared by using a procedure developed by us for the attachment of ligands to liposomes (31, 32) . The procedure uses PEG-PE with the free PEG terminus activated with pNP. Micelles were prepared from PEG-PE with the addition of a small fraction of pNP-PEG-PE. The PE residues form the micelle core, whereas pNP groups allow for fast and efficient attachment of aminogroup-containing ligands via the formation of the urethane (carbamate) bond. Micelle structure and ligand attachment are illustrated in Fig. 1 .
A typical result of micelle-bound antibody quantification is shown in Fig. 2 . About 30% of added 2C5 attached to micelles containing 2 mol percent of pNP-PEG-PE. This corresponds to a Ϸ60% reaction yield because a 2-fold molar excess of protein over pNP-PEG-PE was used to avoid antibody inactivation caused by modification of multiple NH 2 groups. This yield is close to the results obtained for liposomes in a similar procedure (31) . From the yield value, it can be calculated that up to 10 antibody molecules bind to a single micelle. Protein binding to micelles without pNP-PEG-PE was negligible.
Antibody attachment yield may be increased by increasing the molar fraction of pNP-PEG-PE in micelles (Fig. 2) . The yield reached as high as 50% when the micelles contained 8 mol percent of pNP-PEG-PE. Excessive amount of pNP-PEG-PE, however, may cause overmodification of a protein molecule and its inactivation. Therefore, micelles with 2 mol percent of pNP-PEG-PE were used to prepare immunomicelles for all further experiments.
Properties of Immunomicelles.
One of the advantages of micelles as drug carriers is their small size. The transport and accumulation efficiency of microparticulates into the tumor interstitium is limited by their ability to penetrate tumor vascular endothelium (39, 40) . Diffusion and accumulation of microparticles are determined by the cutoff size of the tumor vasculature, and this cutoff size varies for different tumors (41) . If this size is Ͻ200 nm, drug carriers with comparable or larger sizes (liposomes) will not extravasate (42) . Thus, it is important that the modification of micelles with an antibody does not increase their size.
The size distribution of micelles before and after attachment of 2C5 or 2G4 is shown in Fig. 3 . Protein attachment does not affect the micelle size significantly. Dynamic light scattering data were confirmed by the results of freeze-fracture electron microscopy (Fig. 3) . Both the original and 2C5-modified micelles have a spherical shape and a uniform size of Ϸ20 nm. Thus, protein-modified micelles should retain the ability to cross the vasculature even of tumors with a relatively small cutoff sizes that are not accessible with other particulate delivery systems (25, 26, 41) . The binding of 2C5 immunomicelles to the 2C5-specific substrate, nucleosomes, and the binding of 2G4 immunomicelles to the 2G4-specific substrate, cardiac myosin, is shown in Fig. 4 . Both 2C5 and 2G4 immunomicelles bound effectively to monolayers of corresponding antigens. The binding of control micelles (containing no pNP-PEG-PE but prepared following the same protocol and incubated with antibody) was much lower (only background binding can be seen because of some noncovalently adsorbed antibodies). The control with pNP-PEG-PEcontaining antibody-free micelles is not required here, because pNP groups spontaneously hydrolyze under experimental conditions, yielding plain PEG-PE micelles. These results show that 2C5 and 2G4 antibodies preserved their specific activity upon attachment to the micelle surface.
Interaction of Immunomicelles with Cancer Cells in Vitro.
To enhance tumor accumulation, drugs and drug carriers were modified with tumor-specific mAbs (43) (44) (45) . These antibodies are usually tumor type-specific and unable to react with different tumors. Recently, we have shown that certain nonpathogenic monoclo- nal antinuclear autoantibodies, with 2C5 among them, recognize the surface of numerous tumor, but not normal, cells via tumor cell surface-bound nucleosomes (33, 46, 47) . Because these antibodies bind a broad variety of cancer cells, they may serve as specific ligands for the delivery of drugs and drug carriers into tumors.
The results in Fig. 5 clearly show that rhodamine-labeled 2C5 immunomicelles effectively bind to the surface of several unrelated tumor cells lines: human BT20 and murine LLC and EL4 cells. The incubation of antibody-free micelles with the same cells results in virtually no micelle-to-cell association. No binding of 2C5 or 2C5-modified drug carriers with any normal cells was reported (33) . Thus, immunomicelles bearing an antinucleosomal antibody, which recognizes a variety of cancer cells, can specifically attach to these cells in vitro.
Longevity of Immunomicelles in the Blood. Prolonged circulation provides a drug carrier with a better chance to extravasate into the tumor interstitium and͞or interact with ligands on the tumor cell surface. Direct correlation between the ability of a drug carrier to stay in the circulation and its accumulation in tumors was observed for water-soluble polymers (16) and liposomes (13) .
Micelles prepared from PEG-PE are long-circulating (27) . However, antibody attachment to drug carriers might provoke their faster clearance from the circulation because of uptake by Fc receptor-bearing Kupffer cells. To test whether the antibody attachment affects the blood clearance of PEG-PE micelles, we compared clearance characteristics of plain and 2C5-modified micelles in mice. The data in Fig. 6 clearly show that micelle modification with 2C5 had a very small effect on their blood clearance. Elimination profiles of plain and 2C5-modified micelles are almost identical. The data are consistent with earlier observations made with PEG liposomes modified with antimyosin antibodies (48) .
Specific Accumulation of Immunomicelles in the Tumor in Vivo. The enhanced permeability and retention effect-mediated accumulation of drug carriers in tumors depends, among other factors, on tumor vasculature cutoff size (39) . Low vascular permeability prevents many drug carriers, including long-circulating liposomes, from entering certain tumors, such as LLC (41, 42) . Because PEG-based micelles are much smaller than liposomes, they can provide an alternative and more efficient way of drug delivery (26, 27) . The accumulation of plain and immuno-PEG-PE micelles was investigated in LLC tumor in mice. The results shown in Fig. 7 demonstrate that although PEG-PE micelles accumulate in the tumor much better than in normal tissue, their accumulation can be further improved if micelles are additionally modified with tumor-specific antibodies, i.e., converted into immunomicelles. 2C5 immunomicelles accumulate in LLC significantly better (by Ϸ30%) than plain micelles at both investigated randomly chosen time points (Fig. 7 ). An enhanced accumulation of 2C5-targeted micelles over plain micelles in the tumor was observed at 30 min drug-loaded anti-her2 immunoliposomes (49) . The internalization by tumor cells might be highly useful therapeutically for many antitumor agents. For example, a much higher tumor regression rate was observed with a carrier capable of intracellular drug delivery for an equal doxorubicin dose delivered to the tumor (49) .
Tumor Growth Inhibition by Taxol-Loaded 2C5 Immunomicelles. The results of our preliminary proof-of-principle experiments on LLC growth inhibition by different taxol preparations have also confirmed the highest efficiency of taxol-loaded 2C5 immunomicelles among all tested preparations. Even within the model with a randomly chosen and nonoptimized treatment schedule, the average weight of excised tumors in the group treated with taxol incorporated in immunomicelles was 0.67 Ϯ 0.35 g compared with 1.58 Ϯ 0.48 g and 1.37 Ϯ 0.36 g in groups treated with free taxol or taxol in plain PEG-PE micelles, respectively (P Ͻ 0.05 in both cases). The weight of untreated tumors was 2.00 Ϯ 0.60 g. Taxol-free micelles of any composition do not affect tumor growth (Fig. 8) .
Thus, stable PEG-PE-based micelles with an enhanced ability to carry a variety of poorly soluble pharmaceuticals can be transformed into immunomicelles by attaching various specific antibodies to their surface with our method. These micellecoupled antibodies preserve their specific activity. Immunomicelles prepared with cancer-specific 2C5 antibody specifically bind to different cancer cells in vitro and demonstrate increased accumulation in experimental tumors in vivo. This family of pharmaceutical carriers should be very useful for the enhanced delivery of poorly soluble pharmaceuticals to various pathological sites in the body.
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